Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2026-01-08 Report Publication Anno…
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
THX Pharma announces the publication of its letter to shareholders
Report Publication Announcement Classification · 1% confidence The document is a short press release (under 2,500 characters) that explicitly announces the publication of a 'letter to shareholders' and provides a link to download it. According to the 'Menu vs Meal' rule, an announcement stating that a report has been published or is available for download is classified as a Report Publication Announcement (RPA).
2026-01-08 English
THX Pharma annonce la publication de sa lettre aux actionnaires
Report Publication Announcement Classification · 1% confidence The document is a short announcement (2469 characters) from THX Pharma informing shareholders about the publication of their 'lettre aux actionnaires' (shareholder letter). It provides a link to download the document and directs users to the company website. Per the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2026-01-08 French
THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Deputy Chief Executive Officer at THX Pharma. This falls directly under the category of changes in senior management.
2026-01-07 English
THX Pharma annonce la nomination de Julien Veys au poste de Directeur général adjoint
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Deputy General Manager (Directeur général adjoint) at THX Pharma. It details the professional background of the appointee and the strategic context of the appointment. This falls directly under the category of board or management changes.
2026-01-07 French
THX Pharma announces the strong success of its approximately EUR 8 million capital increase to support its continued development and strengthen its financial structure
Share Issue/Capital Change Classification · 1% confidence The document is a press release from THX Pharma announcing the successful completion of a capital increase (share issuance). It details the number of shares issued, the subscription price, the results of the subscription period, the involvement of guarantors, the use of proceeds, and the resulting dilution of share capital. This fits the definition of a 'Share Issue/Capital Change' (SHA) filing, as it describes the mechanics and outcome of a capital raise rather than just an announcement of a report or a general regulatory filing.
2025-11-13 English
THX Pharma annonce le vif succès de son augmentation de capital d'environ 8M EUR pour poursuivre son développement et renforcer sa structure financière
Share Issue/Capital Change Classification · 1% confidence The document is a detailed announcement regarding the successful completion of a capital increase (augmentation de capital) by THX Pharma. It provides specific details on the number of shares issued, the subscription price, the breakdown of demand, the list of guarantors, the use of proceeds, and the impact on shareholding structure (dilution). This falls squarely under the definition of a 'Share Issue/Capital Change' (SHA) filing, as it details the issuance of new shares and the resulting changes to the company's capital structure.
2025-11-13 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.